Does HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect?Zacks Investment Research • 11/14/23
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/26/23
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 09/25/23
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/14/23
Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should KnowZacks Investment Research • 06/07/23
How Much Upside is Left in HilleVax, Inc. (HLVX)? Wall Street Analysts Think 87.76%Zacks Investment Research • 05/22/23
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/12/23
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine CandidateGlobeNewsWire • 04/25/23
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 03/17/23
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)Zacks Investment Research • 12/14/22
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)Zacks Investment Research • 12/13/22
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine CandidateGlobeNewsWire • 12/05/22
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)Zacks Investment Research • 11/18/22
Wall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should KnowZacks Investment Research • 11/15/22
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine ForumGlobeNewsWire • 08/15/22
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/10/22